World Cancer Research Fund International (WCRF International)/AICR (American Institute for Cancer Research)

WCRF/AICR will keep you informed with the latest updates on the Second Expert Report, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective.

World Cancer Research Fund International First Floor 19 Harley Street London, W1G 9QJ, UK Tel: +44-20-73434200 | Fax: +44-20-73434220 http://www.wcrf.org/

American Institute for Cancer Research 1759 R Street N.W. Washington, DC 20009, USA Tel: 202-328-7744 | Fax: 202-328-7226 http://www.aicr.org/

Adhesion prevention in gynaecological surgery

Characteristics and prognosis of coexisting adnexa malignancy with endometrial cancer: a single institution review of 51 cases

CONCLUSION:
Our results showed that OS and PFS of synchronous primary ovarian cancer in patients with endometrial cancer is better than those with ovarian metastasis patients. Pre- and intra-operative, intensive and careful assessment, and strict and continuous postoperative surveillance should pay attention to the endometrial cancer patients who preserved ovary for having possibility of coexisting occult ovarian lesions.

full free access: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers -- Journal of Medical Genetics

"Besides the high risk of developing colorectal carcinomas of 10–80%, Lynch syndrome family members are at increased risk of developing several extra-colonic cancers and tumours at a relatively young age: endometrial cancer, carcinomas of the ovary, small bowel and biliary tract cancer, sebaceous gland tumours and urothelial carcinomas (UC) of the upper urinary tract. The lifetime risk of upper urinary tract cancer in Lynch syndrome varies in different studies from 0.4–20%. Microsatellite instability (MSI) is present in these urothelial carcinomas of the upper urinary tract."

See Table 1

abstract/free full access: Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

"The majority of the studies were on women with advanced or metastatic breast cancer. Twenty-one studies included participants with myeloma, lymphoma, sarcoma or ovarian cancer, and three studies included a mixture of tumour types."

 Background

We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.

Conclusions

Evidence is not sufficiently robust to support clear evidence-based recommendations on different anthracycline treatment regimens, or for routine use of cardiac protective agents or liposomal formulations. There is a need to improve cardiac monitoring in oncology trials.